• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Recent advances in siRNA delivery systems for prostate cancer therapy
Curr Pharm Biotechnol. 2021 Jun 15. doi: 10.2174/1389201022666210615123211. Online ahead of print.ABSTRACTThe critical problems of conventional prostate cancer therapeutic strategies like nonspecific toxicity and multi-drug resistance prompted the development and application of countless nanoparticle-based siRNA therapeutics. The main challenges to siRNA-based therapeutics becoming a new paradigm in the treatment of prostate cancer stem from the lack of safe and effective delivery systems, immune system stimulation, poor knowledge of nano-bio interactions, and limitations concerning designing, manufacturing, clinical trans...
Source: Current Pharmaceutical Biotechnology - June 16, 2021 Category: Biotechnology Authors: Shahin Aghamiri Pourya Raee Shiva Shahmohamadnejad Sasan Shabani Jaber Ghorbani Marzieh Sameni Mohammad Taha Ebrahimi Source Type: research

Silencing of BACH1 inhibits invasion and migration of prostate cancer cells by altering metastasis-related gene expression.
CONCLUSIONS: BACH1 is overexpressed in prostate cancer. Because this promotes invasion and migration, it may facilitate metastasis of prostate cancer. Thus, BACH1 is a potential therapeutic target for metastatic prostate cancer. BACH1 silencing therapy can be considered as a novel and effective adjuvant in prostate cancer targeted therapies. PMID: 28889753 [PubMed - as supplied by publisher]
Source: Artificial Cells, Nanomedicine and Biotechnology - September 12, 2017 Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research

Tristetraprolin regulates prostate cancer cell growth through suppression of E2F1.
Abstract The transcription factor E2F1 is active during the G1 to S transition and is involved in cell cycle and progression. A recent study reported that increased E2F1 is associated with DNA damage and tumour development in several tissues using transgenic models. Here, we show that E2F1 expression is regulated by tristetraprolin (TTP) in prostate cancer. Overexpression of TTP decreased the stability of E2F1 mRNA and the expression level of E2F1. In contrast, inhibition of TTP using siRNA increased the E2F1 expression. E2F1 mRNA contains three AREs within the 3'UTR and TTP destabilized a luciferase mRNA that con...
Source: Journal of Microbiology and Biotechnology - October 22, 2013 Category: Biotechnology Authors: Lee HH, Lee SR, Leem SH Tags: J Microbiol Biotechnol Source Type: research